A 1.2-kb cDNA fragment encoding a platelet 47-kDa protein has been isolated from a human bone marrow cDNA library by using a degenerate oligonucleotide of the sequenced amino terminus of the purified platelet protein with a poly(dT) 12 ⅐(dG) by polymerase chain reaction. A computer search revealed that the cDNA represents the coding sequence of a protein with a fragmentary homology to several proteins. Using a prokaryotic expression system, pBad TOPO-47 cDNA, a 47-kDa recombinant protein was obtained and purified to apparent homogeneity by nickel-nitrilotriacetic acid resin and collagen affinity column. The recombinant protein binds to type III but not type I collagenSepharose 2B affinity columns. Anti-47-kDa but not anti-65-kDa antibody inhibits the binding of the recombinant protein to the type III collagen-coated micro titer wells in a dose-dependent manner. Like the receptor protein purified from platelet membranes, the recombinant protein inhibits type III collageninduced platelet aggregation also in a dose-dependent manner. We have defined two active peptides from the cloned deduced amino acid sequence. Both peptides inhibit type III but not type I collagen-induced platelet aggregation in a dose-dependent fashion. These results suggest that the active binding site of the platelet receptor to type III collagen resides in these portions of the protein.
Ligand-receptor interactions with the subsequent transduction of signals have long been recognized as a major mechanism for regulating cellular activities in eukaryotic cells. This mechanism is also operative when platelets interact with collagen exposed by damage to the endothelial surfaces of vessels. In blood vessels, type I and type III collagens are the major collagen components. Vessels also contain very small amounts of type IV and V collagen and minor amounts of several other types of collagen. After platelets adhere to exposed connective tissue, they aggregate, secrete biologically active substances, and effect hemostasis. Many studies have centered on the role of the integrin and non-integrin collagen receptors in regulating platelet function, and it has been known that platelets possess additional, distinct reactive sites for type I collagen (1, 2) and type III collagen (3) (4) (5) . However, definition of the platelet collagen receptors must be fully established before logical interventions can be identified and used to alter the course of abnormal hemostasis when platelets encounter denuded vascular surfaces.
We have cloned and characterized a non-integrin platelet receptor for type I collagen (6) . Expression and characterization of the recombinant protein were accomplished, and the protein was shown to be functionally significant in blocking the interaction between type I collagen and human platelets. We have defined nine amino acid residues (Nona peptide) representing a part of the extracellular domain of the 65-kDa receptor that blocks type I collagen-induced platelet aggregation and the release reaction (7) . The peptide completely blocks the adhesion of platelets to type I collagen immobilized on micro titer wells and blocks 60% of the adhesion in aortic segments. However, the recombinant protein and the peptide do not affect type III collagen or the ADP-induced platelet aggregation and the release reaction. These results suggest that platelet receptors for type I and type III collagens are different. Determination of the precise receptor for each type of collagen is clearly necessary to understand platelet-collagen interaction.
Previously, we have purified and characterized a platelet membrane protein with a molecular mass of 47 kDa that functioned as a receptor for type III collagen in intact platelets. The polyclonal antibody raised against the purified 47-kDa protein also inhibits type III collagen-induced platelet aggregation (8) . However, the protein had not been completely characterized. In the present study, a cDNA encoding the 47-kDa protein has been derived and a recombinant protein has been expressed in a prokaryotic expression vector. We show that the recombinant protein binds to type III collagen in a dose-dependent manner. The recombinant protein inhibits type III collagen-induced platelet aggregation in a dose-dependent manner. Furthermore, we have defined two active peptides that are able to specifically inhibit type III but not type I collagen-induced platelet aggregation.
EXPERIMENTAL PROCEDURES
Cloning of a Platelet 47-kDa Protein-The platelet 47-kDa protein (molecular mass 47 kDa) was purified from isolated human platelet membranes as previously described, and a polyclonal antibody (anti-47-kDa (polyclonal antibody raised against the purified receptor for type III collagen)) was raised. The anti-47-kDa reacts with the recombinant protein in Western blots (8) . We have also determined the amino terminus sequence of the 47-kDa platelet protein so that a degenerate oligonucleotide could be designed. We used the degenerate oligonucleotide and poly(dT) 12 ⅐(dG) to screen a human bone marrow cDNA library.
The cDNA fragment (1.2-kb) was ligated into a pBad TOPO prokaryotic expression vector (Stratagene, La Jolla, CA), heat-shocked into * This work was supported partly by the Office of Research and Development, Medical Research Service, Department of Veterans Affairs, National Institutes of Health, and the Arthritis Foundation. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact. competent Escherichia coli, and grown on liquid broth (LB) 1 agar plates. Distinct single colonies were picked and regrown in LB with 50 g/ml ampicillin in the presence of 1 mM arabinose for 6 h in a shaker. Protein from cell extracts was analyzed by Western blot using anti-47-kDa (8) .
Western Blot-Samples were separated by 10% SDS-PAGE (9) and electrophoretically transferred onto a nitrocellulose sheet (9 -11), followed by treatment with 3% dried milk in 20 mM Tris, 500 mM NaCl, Tween 20 (0.25 ml/liter v/v), pH 7.4 (TBS) to eliminate nonspecific binding. The nitrocellulose sheet was then washed three times with TBS and incubated with anti-47-kDa IgG (2 g/ml) overnight at 4°C. After washing three times in TBS, the nitrocellulose sheet was incubated with a second antibody (peroxidase-conjugated goat anti-rabbit IgG, 1/20,000) for 1 h at room temperature. After washing three times with TBS and once with 20 mM Tris-HCl, pH 7.4, the nitrocellulose sheet was developed with enhanced chemiluminescence (ECL) developing solutions as described by the manufacturer (Amersham Biosciences).
Purification of Recombinant Protein-Transformed bacteria (E. coli) containing the pBad TOPO-47 cDNA were grown overnight in LB containing ampicillin. Cells were harvested and washed with 20 mM phosphate buffer containing 130 mM NaCl, pH 7.4 (PBS), followed by resuspension in 50 mM Tris-HCl, pH 7.4. Cells were then broken with a French press and centrifuged for 30 min at 15,000 ϫ g. The supernatant was subjected to a nickel-nitrilotriacetic acid resin column or an affinity column using type III collagen coupled to Sepharose 4 B. The column was equilibrated and washed with PBS. The bound protein was eluted with 4 M urea in 50 mM Tris-HCl, pH 7.4, and dialyzed with distilled water (three changes) at 4°C. The dialyzed pool fraction was concentrated and reconstituted in PBS and redialyzed against the same buffer. The protein concentration was determined by the method of Lowry et al. (12) .
Preparation of Platelet-rich Plasma (PRP)-Human blood (nine parts) was collected from normal volunteers after an overnight fast in polypropylene tubes containing 1 part 3.8% sodium citrate. PRP was prepared by centrifuging the citrated blood at room temperature for 10 min at 226 ϫ g (13) . Whole blood and PRP were exposed to plastic surfaces or siliconized vessels only. Platelet counts of the PRP ranged from 200,000 to 300,000 per mm 3 . Platelet Aggregometry-Platelet aggregation was assayed by the turbidimetric method of Born (14) using a ChronoLog Lumi aggregometer (ChronoLog Corp., Havertown, PA). An aliquot of 0.45 ml of PRP was pipetted into a small siliconized cuvette and stirred at a constant speed of 1100 rpm at 37°C. The changes in percent transmission were recorded continuously.
Preparation of Washed Platelets-Equal volumes of PRP and 20 mM Tris-HCl, 130 mM NaCl, and 1 mM EDTA, pH 7.4 (Tris-NaCl-EDTA) were mixed together and centrifuged at 1000 ϫ g for 5 min. The pellet formed was washed once with Tris-NaCl-EDTA and then suspended in the same buffer at a concentration of 400,000 -600,000 platelets/mm 3 .
Labeling of Platelets with [
14 C]Serotonin-An aliquot (20 l) of [ 14 C]serotonin (specific activity 51.5 mCi/mmol) was added into PRP (20 ml) and incubated at room temperature for 30 min. At the end of the incubation, an equal volume of Tris-EDTA was added before centrifugation at 500 ϫ g for 10 min. The pellets were resuspended in 20 ml of Tris-EDTA and centrifuged again. The platelets were then resuspended in Tris-EDTA at a concentration of 400,000 -600,000 platelets/mm 3 (13) . Preparation of Type I and Type III Collagens-Neutral salt soluble collagen (type I and type III) was extracted from human placenta (collected from a local hospital after full-term delivery). The extracted collagens were purified by different salt concentrations as previously described (15, 16) . The type I collagen solution was also purchased from ChronoLog Corp.
Labeling the r47 Protein by Using 5(6)-Carboxyfluorescein-Nhydroxysuccinimide Ester-The purified r47 protein (47-kDa recombinant protein) was incubated with 5(6)-carboxyfluorescein-N-hydroxysuccinimide ester (FLUOS) according to the manufacturer's procedure (Roche Molecular Biochemicals). Briefly, 0.5 mg of the purified recombinant protein (dissolved in 0.5 ml of PBS) was incubated with 50 g of (1:10) FLUOS for 2 h with stirring at room temperature (protected from light). The bound FLUOS and unbound FLUOS were separated with a Sephadex column and eluted with PBS. The bound FLUOS-recombinant protein fractions were collected.
Collagen-coating of Micro Titer
Wells-Aliquots of 100-l volume containing various amounts of type III collagen (0.5, 1, 2, 5, 10, 20, or 40 g) in phosphate buffer, pH 7.6, were added into micro titer wells and incubated at 4°C overnight. Wells were washed with PBS and incubated with 0.1% bovine serum albumin (150 l/well) for 30 min at room temperature. The wells were washed with PBS again before the addition of FLUOS-labeled recombinant protein. At the end of incubation, the wells were washed three times with PBS. A BioRad Fluoromark was used to detect the bound FLUOS-recombinant protein.
Adhesion of Platelets to the Artificial Matrix-An aliquot (1 ml) of r47 protein or control protein was placed on the artificial matrix (human type III) and incubated at room temperature for 10 min. Following incubation, an aliquot of washed 14 C-labeled platelets was added to each Petri dish and incubated for an additional 20 min. The Petri dishes (Nalge Nunc, Denmark) were washed five times (2 ml each) with Tris-EDTA. The attached platelets were detached with 10 ml of ScintiVerse BD (2 ml/time). Radioactivity was assessed with a Packard Scintillation counter (6) .
Adhesion of Platelets to Rabbit Aortic Segments-Aortas from rabbits were dissected from the surrounding tissues, the endothelia were denuded with a rubber policeman, and aortas were cut into segments. Aortic segments (0.8 g, wet weight) were incubated with either recombinant protein or control protein for 10 min. At the end of incubation, an aliquot of 14 C-labeled platelets was added to each sample, and the preparation was incubated for an additional 20 min. The aortic segments were washed with 12 ml (3 ml each ϫ 4) of Tris-EDTA buffer, and the radioactivity recovered was measured in a scintillation counter in the presence of 10 ml of ScintiVerse BD (7).
RESULTS

Tissue Distribution of the 47-kDa Protein-We have used
Western blot analyses to examine the existence of the 47-kDa protein in mouse tissues and platelets (Fig. 1) . Based on the same amount of protein (Lowry determination) used, there are differences in band intensity of the Western blot. The 47-kDa protein exists in all the rat tissues and platelets examined.
Determination of the Amino Terminus Sequence-Purified platelet 47-kDa protein was analyzed with 10% SDS-PAGE and electrophoretically transferred onto a polyvinylidene difluoride membrane. The membrane was stained with Amido Black and destained with water. The corresponding spot was excised and subject to determination of the amino terminus sequence by a sequencer (Applied Biotechnology). The determined sequence is DARKSEV.
Establishment of the Primary Structure of the Platelet 47-kDa Protein-The strategy for cloning the cDNA (which encodes the 47-kDa protein) was using the polymerase chain FIG. 1 . The distribution of the 47-kDa protein in mouse tissues and platelets. Mouse tissues (100 g of extracts of heart, brain, liver, lung, spleen, kidney, muscle, platelets, and human platelets for lanes 1, 2, 3, 4, 5, 6, 7, 8 , and 9, respectively) were analyzed with 10% SDS-PAGE, transferred onto nitrocellulose paper, analyzed by Western blot with the anti-47-kDa, and developed with substrate (horseradish peroxidase reagent 90 mg, 30 ml of methanol, and 30 l of H 2 O 2 added up to 120 ml with 20 mM Tris, pH 7.4). Lane 10 is the BioRad prestained molecular mass markers (kDa).
reaction with a degenerate oligonucleotide and poly(dT) 12 ⅐(dG). A 1.2-kb cDNA fragment was obtained, gel purified, subcloned into pBad TOPO prokaryotic expression vector, and sequenced by using custom designed primers (Fig. 2) . The open reading frame represented by 1065 bases of this cDNA with the TAA stop codon at position 1063. A segment of base pairs from the untranslated region of the 5Ј end was also identified (data not shown). A computer search of the gene bank, however, did not find any significant homology. The calculated molecular mass of the recombinant protein is 42 kDa.
Purification of the Recombinant Protein-The recombinant protein from the pBad TOPO-47 cDNA expression vector was expressed in E. coli (Fig. 3A) (compare lane 1 to lane 2 for pBad TOPO-47 cDNA and mock-transfected cell extracts, respectively). The crude protein from the cell extract was purified through binding of the hexahistidine tag (located at the aminoterminal end of the protein) to the nickel-nitrilotriacetic acid resin column. It was further purified by type III collagen affinity column chromatography. The degree of purification of the recombinant protein was examined by 7.5% SDS-PAGE. A single band with a molecular mass of 47 kDa was obtained (Fig. 3B) . 
FIG. 2-continued
Collagen-Platelet Interaction
Binding of the Recombinant Protein to Type III CollagenSeveral experiments were performed to investigate whether the isolated recombinant protein could specifically bind to type III collagen. In the first set of experiments, the recombinant protein extracts were applied to affinity columns of type I collagen-Sepharose 2B and type III collagen-Sepharose 2B. The recombinant protein bound to type III collagen but not to type I collagen-Sepharose 2B (data not shown).
Because the r47 protein cannot be phosphorylated, we have used FLUOS-labeled r47 protein to perform additional experiments. Varying amounts of the FLUOS-labeled recombinant protein were incubated on type III collagen-coated micro titer wells and the amount of fluorescence was measured by a BioRad Fluoromark. As shown in Table I , binding was dependent on the amount of FLUOS-labeled r47 protein added. Binding was inhibited by a 10-fold excess of unlabeled recombinant protein indicating that the binding is specific. At the highest concentration of FLUOS-labeled r47 protein, the FLUOSlabeled r47 protein binds to type I collagen-coated micro titer wells, but the binding of FLUOS-labeled r47 protein could not be replaced by the addition of a 10-fold excess of non-labeled r47 protein. Moreover, binding could be inhibited in a dosedependent manner by anti-47-kDa (anti-platelet receptor for type III collagen) (8) but not by anti-65-kDa (anti-platelet receptor for type I collagen) (6) as shown in Table II . There was no demonstrable binding of the labeled recombinant protein to laminin-and fibronectin-coated micro titer wells (data not shown).
Effects of the Purified Recombinant Protein on Platelet Function-In previous studies we have shown that the 47-kDa protein was isolated and purified from platelets and could competitively inhibit type III collagen-mediated platelet aggregation (6) . We, therefore, tested the effect of the purified recombinant and 2 g, respectively) . After the pre-incubation, an aliquot of 0.45 ml of PRP was added to the cuvette, and platelet aggregation was monitored with a ChronoLog platelet aggregometer.
TABLE I Binding of FLUOS-labeled recombinant protein to type I and type III
collagens-coated micro titer wells Micro titer wells were coated with 100 l of type I or type III collagen (50 g) in 120 mM phosphate buffer, pH 7.6, at 4°C overnight. The wells were washed with PBS three times. Various amounts of FLUOS-labeled recombinant protein (total volume ϭ 100 l) were added to the wells followed by incubation at room temperature for 30 minutes. At the end of incubation, each well was washed with PBS (100 l) three times. The bound FLUOS-labeled recombinant protein was detected by a BioRad Fluoromark (excitation set at 485 nm and emission at 538 nm). Data are expressed as mean Ϯ S.D. of triplicate experiments. Table I . Various amounts of anti-47-kDa and anti-65-kDa were added to test tubes containing 2 g of FLUOSlabeled recombinant protein in a final volume of 100 l and incubated at room temperature for 30 minutes. The incubated materials were then transferred to PBS-washed micro titer wells that were coated with type III collagen and incubated for another 30 minutes. At the end of incubation, these wells were washed with PBS, and the bound FLUOSlabeled r47 protein in each dish was assessed as described in Table I 
protein on type III collagen-induced platelet aggregation (Fig. 4) . Fig. 4A shows type III collagen-induced platelet aggregation in a dose-dependent manner (curves a, b, c, and d are PBS control, 0.25, 0.5, and 1 g, respectively). Fig. 4B shows the inhibitory effect of the purified recombinant protein (10, 20, and 40 for curves d, c, and b, respectively) on type III collagen (0.5 g)-induced platelet aggregation. Both 20 and 40 g of r47 protein were completely inhibited platelet aggregation (B, curves b and c). The 10 g of r47 protein has less inhibition on 0.5 g of collagen-induced platelet aggregation (B, curve d). We then fixed the r47 protein (20 g) and varied the amounts of collagen (0.5, 1, and 2 g for C, curves b, c, and d, respectively). Results showed that the inhibitory effect of the r47 protein can be relieved by higher amounts of collagen.
The effect of the purified r47 protein on type III collageninduced platelet protein phosphorylation was also examined (Fig. 5) . There are two platelet proteins with a molecular mass of 47 and 22 kDa, respectively, which showed an increase in radiolabeled phosphate incorporation by collagen (0.5 g) compared with PBS control (lane 2 compared with lane 1). The pre-incubation of collagen (0.5 g) with various amounts of r47 protein inhibits phosphorylation of both platelet proteins (lanes 3, 4, and 5 for 40, 20, and 10 g, respectively).
We then analyzed the deduced amino acid sequence with a hydrophilicity plot to identify the extracellular domains (data not shown). We have defined four outer surface domains, chemically synthesized four peptides, and tested their ability to inhibit type III collagen-induced platelet aggregation. We have found two peptides that inhibit type III collagen-induced platelet aggregation (Fig. 6) . One of the active peptides is located at the amino terminus end.
In conclusion, we have isolated a cDNA fragment for encoding a platelet protein, which is recognized by a polyclonal antibody raised against the platelet 47-kDa protein. The recombinant protein and its derived synthesized peptides resemble the platelet 47-kDa protein and are able to inhibit type III but not type I collagen-induced platelet aggregation. DISCUSSION We have cloned a 1.2-kb cDNA with a functional open reading frame from the human bone marrow cDNA library using the polymerase chain reaction. The cDNA fragment was purified and subcloned into a prokaryotic expression vector (pBad TOPO) and a recombinant protein was expressed and purified to apparent homogeneity as shown on 7.5% SDS-PAGE. The calculated (from amino acid composition) molecular mass of this recombinant protein is 45 kDa and it is recognized by anti-47-kDa in Western blots.
Type III collagen-induced platelet aggregation was inhibited by the pre-incubation of the recombinant protein with type III collagen in a dose-dependent manner. Pre-incubation of platelets with the recombinant protein did not inhibit type III collagen-induced platelet aggregation. This observed effect suggests that the recombinant protein binds to type III collagen. Data from binding of the radiolabeled r47 protein to collagenSepharose 2B columns suggest that the r47 protein binds to type III collagen. This result is consistent with our earlier report that the anti-47-kDa inhibits type III collagen-induced platelet aggregation (8) .
Binding of FLUOS-labeled r47 protein to type I collagencoated micro titer wells can only be obtained at a high concentration. The high concentration binding could not be replaced with a 10-fold excess of non-labeled r47 protein. From the comparison of the r47 protein inhibition on type I and type III collagen-induced platelet aggregation and the binding data, we may draw the conclusion that the binding is nonspecific or that the binding site may be different.
We have also defined two peptides that inhibit type III collagen-induced platelet aggregation (Fig. 6) 4 ]inorganic phosphate (500 Ci/ml) for 60 min and washed with Tris-EDTA. The washed platelets suspension was added to the r47 protein (lanes 1, 2, 3, 4 and 5 are PBS, 0.5 g of type III collagen, and 0.5 g of type III collagen pre-incubated with r47 protein, 10, 20, and 40 g, respectively) and incubated for 3 min. The reaction was stopped with SDS-PAGE sample buffer, boiled for 3 min, and analyzed with 10% SDS-PAGE. The gel was stained with Coomassie Brilliant Blue, destained with acetic acid-methanol. Radioautogram was obtained by contacting the dried gel with x-ray film.
FIG. 6.
Chemically synthesized peptides inhibit type III collagen-induced platelet aggregation. A shows PBS (curve a) and type III collagen-induced platelet aggregation (0.25 g of collagen type III, curve b). B shows that various amounts of peptide 1 shown in bold letters in Fig. 2 (a, b, and c for 60, 30 , and 15 g, respectively) inhibit type III collagen (0.25 g)-induced platelet aggregation. C shows identical experiment conditions as B except that peptide 1 was replaced with peptide 2 shown in bold and italicized letters in Fig. 2. acid sequence of those two peptides is different from the existing known sequences of peptide inhibitors suggesting that there is more than one site for platelets to react with collagen (6, 7) .
It has been reported that platelet receptors for type I and type III collagens are different based on different approaches (1) (2) (3) (4) (5) . In the present investigation, we have shown that the amino acid residues of active sites are different from the type I receptor site. These results further indicate that there are different reactive sites for type I and type III collagens. Interestingly, the platelet receptor for type III collagen possesses two binding sites compared with one site for the type I collagen (7) . One of these active peptides is located at the amino terminus of the extracellular domain. The location may be more assessable to bind type III collagen. Determining if this is the reason for type III collagen reacting more efficiently to platelets will require further studies entailing switching the positions of the active site. The platelet receptor for type III collagen is more hydrophobic than the platelet receptor for type I collagen (the 65-kDa protein) (6).
Monnet and Fauvel-Lafeve (5) have described a platelet receptor that binds type III collagen specifically. The protein has a molecular mass of 68 -72 kDa and does not correspond to any other already known platelet collagen receptor including the presently described platelet receptor for type III collagen. These results indicate that there are more than one platelet receptors for type III collagen.
Taken together, our current data strongly suggest that the recombinant protein encoded by the 1.2-kb-cloned cDNA is a platelet 47-kDa protein. This postulation is based on five supporting findings. First, the polyclonal antibody raised against the platelet-purified 47-kDa protein recognizes the recombinant protein. Second, the purified r47 protein binds to type III collagen-Sepharose 2B column and type III collagen-coated micro titer wells. Third, the purified recombinant protein inhibits type III collagen-induced platelet aggregation in a dose-dependent manner and can be reversed by adding higher amounts of type III collagen. Fourth, the inhibitory effect of the recombinant protein on platelet aggregation requires the pre-incubation of the recombinant protein with type III collagen. And finally, the binding of the recombinant protein to type III collagen-coated micro titer wells is inhibited by anti-47-kDa but not anti-65-kDa in a dosedependent manner.
